Terpyridine

Terpyridine

SCHEMBL7108795

C=C(c1ccncc1)c1ccncc1.[Pt].[Pt].c1ccc(-c2cccc(-c3ccccn3)n2)nc1.c1ccc(-c2cccc(-c3ccccn3)n2)nc1

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.60
L3MBTL1 Q9Y468 5/20 0.60
SMN1; SMN2 Q16637 5/20 0.60
TP53 P04637 4/20 0.60
TDP1 Q9NUW8 4/20 0.60
ALOX15 P16050 4/20 0.60
CCR1 P32246 3/20 0.60
CCR5 P51681 3/20 0.60
CCR8 P51685 3/20 0.60
LMNA P02545 3/20 0.60
HTT P42858 2/20 0.60
ALPL P05186 2/20 0.60
HSP90AA1 P07900 1/20 0.60
ALPI P09923 1/20 0.60
ALPG P10696 1/20 0.60
MAPK1 P28482 1/20 0.60
P4HTM Q9NXG6 2/20 0.47
CYP1A2 P05177 1/20 0.47
POLB P06746 1/20 0.47
METAP1 P53582 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7548441 0.86 CCR1 (0.66) KDM4EL3MBTL1SMN1; SMN2TP53TDP1
Dipyridyl SCHEMBL28995270 0.82 KDM4E (0.64) KDM4EL3MBTL1SMN1; SMN2TP53TDP1
Terpyridine SCHEMBL7112915 0.80 KDM4E (0.95) KDM4EL3MBTL1SMN1; SMN2TP53TDP1
Terpyridine SCHEMBL1616654 0.80 KDM4E (0.95) KDM4EL3MBTL1SMN1; SMN2TP53TDP1
SCHEMBL7549260 0.79 CCR1 (0.59) KDM4EL3MBTL1SMN1; SMN2TP53TDP1
SCHEMBL7549135 0.78 LMNA (0.41) KDM4EL3MBTL1SMN1; SMN2TP53TDP1
Terpyridine SCHEMBL2406854 0.78 KDM4E (0.82) KDM4EL3MBTL1SMN1; SMN2TP53TDP1
SCHEMBL6246649 0.78 KMT2A (0.60) KDM4EL3MBTL1SMN1; SMN2HTTCYP1A2
Terpyridine SCHEMBL30610403 0.78 KDM4E (0.90) KDM4EL3MBTL1SMN1; SMN2TP53TDP1
Terpyridine SCHEMBL57442 0.78 KDM4E (1.00) KDM4EL3MBTL1SMN1; SMN2TP53TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0885233-B1 TERPYRIDINE-PLATINUM(II) COMPLEXES ISIS INNOVATION (GB) 2002-06-19 EP claimed
EP-1144423-B1 BIS-TERPYRIDINE-PLATINUM(II) COMPLEXES ISIS INNOVATION (GB) 2003-10-22 EP disclosed
EP-0885233-B1 TERPYRIDINE-PLATINUM(II) COMPLEXES ISIS INNOVATION (GB) 2002-06-19 EP disclosed
US-20020013306-A1 TERPYRIDINE-PLATINUM(II) COMPLEXES ISIS INNOVATION LIMITED (GB) 2002-01-31 US disclosed
EP-1164138-A1 Terpyridine-platinum (II) complexes ISIS INNOVATION LIMITED (GB) 2001-12-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013306-A1 TERPYRIDINE-PLATINUM(II) COMPLEXES TOP2A, TOP1, TOP2B KDM4E 4584/4885L3MBTL1 2025/4885SMN1; SMN2 3661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.